Neonates With Acute Seizures May Be Overmedicated
Those discontinuing seizure meds after symptom resolution in the hospital have same neurodevelopment, epilepsy outcomes at 24 months
Epilepsy
Room Temperature Stable Fosphenytoin Gets FDA Approval
The product is a ready-to-dilute, room temperature stable formulation of fosphenytoin for IV injection, which allows for point-of-care storage.
FDA Requires Boxed Warning Update for Benzodiazepines
Benzodiazepines are widely used to treat a variety of conditions including anxiety disorders, insomnia and seizures.
Epidiolex Approved for Tuberous Sclerosis Complex-Associated Seizures
Epidiolex is a pharmaceutical formulation of highly purified cannabidiol.
Unapproved Cannabidiol, Curcumin Injectables Marketed for Multiple Disorders Recalled
Biota Biosciences announced the voluntary recall of CBD Complex, Curcumin Complex, and Cannabidiol + Curcumin Injectables due to the products being marketed without the approval of the FDA.
DEA Deschedules Prescription CBD Drug Epidiolex
Epidiolex® (cannabidiol; GW Pharmaceuticals) oral solution is no longer a controlled substance, according to the Drug Enforcement Administration.
Epidiolex Gets Priority Review for Tuberous Sclerosis Complex-Associated Seizures
The FDA has accepted for Priority Review the supplemental New Drug Application for Epidiolex.
Valtoco Nasal Spray Now Available for Seizure Clusters
Neurelis announced the availability of Valtoco® (diazepam nasal spray) for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (ie, seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients aged ≥6 years.
Valtoco Nasal Spray Approved for Seizure Clusters
The FDA has approved Valtoco (diazepam nasal spray; Neurelis) for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity that are distinct from a patient’s usual seizure pattern in patients with epilepsy 6 years of age and older.
Antiepileptic Drug Exposure Low in Breastfeeding Infants
Median percentage of infant-to-mother AED concentration ranged from 0.3 to 44.2 percent
